Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
News Oct 20, 2016
Agilent Technologies Inc has named Roeland G.W. Verhaak, Ph.D., as the winner of the company’s prestigious Early Career Professor Award. Dr. Verhaak has been selected for his contributions to the implementation of transcriptomics, genomics, and big-data analysis to the classification and diagnosis of various cancer types, including acute myeloid leukemia and glioblastoma. His approach and results spearheaded the implementation of the molecular analysis of cancer.
Dr. Verhaak recently joined The Jackson Laboratory (JAX) as professor and associate director of computational biology. “Dr. Verhaak is recognized internationally for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches. His data-driven, unbiased analyses of cancer genomics and profound understanding of cancer biology are improving our ability to identify clinically relevant subtypes of cancer,” said Jack Wenstrand, Agilent's director of university relations and external research.
"Agilent is pleased to recognize Dr. Verhaak with this award and to support his important research at JAX." “We’re so pleased that Dr. Verhaak has received this prestigious award in recognition of his outstanding work in advancing human health,” said Charles Lee, Ph.D., FACMG, scientific director and professor at JAX Genomic Medicine.
The annual Agilent Early Career Professor Award was established in 2008. Through this award, Agilent seeks to recognize the achievements of academic researchers in the early stages of their careers and to establish strong collaborative relationships with them early in their professional lives.
This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.